Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?

BACKGROUND: Pharmacologic options for treatment of osteolytic diseases especially in children are limited. Although not licensed for use, denosumab, a fully humanized antibody to RANKL, is used in children with good effects. Among others, one possible indication are giant cell tumors and aneurysmati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sydlik, Carmen, Dürr, Hans Roland, Pozza, Susanne Bechtold-Dalla, Weißenbacher, Claudia, Roeb, Julia, Schmidt, Heinrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515853/
https://www.ncbi.nlm.nih.gov/pubmed/32776272
http://dx.doi.org/10.1007/s12519-020-00378-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515853/
https://www.ncbi.nlm.nih.gov/pubmed/32776272
http://dx.doi.org/10.1007/s12519-020-00378-w

Ejemplares similares